Literature DB >> 16219805

Up-regulation of CD36/FAT in preadipocytes in familial combined hyperlipidemia.

Steven J R Meex1, Carla J H van der Kallen, Marleen M J van Greevenbroek, Petra M H Eurlings, Mohammed El Hasnaoui, Chris T A Evelo, Patrick J Lindsey, Joost J F P Luiken, Jan F C Glatz, Tjerk W A de Bruin.   

Abstract

Familial combined hyperlipidemia (FCHL) shows many features of the metabolic syndrome. The strong genetic component makes it an excellent model to study the genetic background of metabolic syndrome and insulin resistance. Adipose tissue is believed to contribute to, or even underlie, the FCHL phenotype and is an interesting target tissue for gene expression studies. However, interpretation of adipose tissue gene expression experiments is complex since expression differences cannot only arise as a direct consequence of a genetic trait, but may also reflect an adaptation to metabolic influences at the cellular level. In the present study, we measured gene expression levels in cultured primary human preadipocytes from FCHL and control subjects. Since isolated preadipocytes were allowed to replicate for weeks under standardized conditions, the contribution of previous metabolic influences is rather small whereas genetic defects are preserved and expressed in vitro. The main finding was up-regulation of CD36/FAT in FCHL preadipocytes, confirmed in two independent groups of subjects, and a concomitant increase in CD36/FAT-mediated fatty acid uptake. CD36/FAT overexpression has previously been shown to be associated with other insulin-resistant states. The present data suggest that CD36/FAT overexpression in FCHL occurs very early in adipocyte differentiation and may be of genetic origin.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16219805     DOI: 10.1096/fj.04-2403fje

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  7 in total

1.  Association of CD36 gene variants and metabolic syndrome in Iranians.

Authors:  Azita Zadeh-Vakili; Bita Faam; Maryam S Daneshpour; Mehdi Hedayati; Fereidoun Azizi
Journal:  Genet Test Mol Biomarkers       Date:  2011-11-02

2.  FABP4 plasma levels are increased in familial combined hyperlipidemia.

Authors:  Anna Cabré; Iolanda Lázaro; Montserrat Cofán; Estibaliz Jarauta; Núria Plana; Angel L Garcia-Otín; Juan F Ascaso; Raimón Ferré; Fernando Civeira; Emilio Ros; Lluís Masana
Journal:  J Lipid Res       Date:  2010-05       Impact factor: 5.922

3.  Fyn-dependent regulation of energy expenditure and body weight is mediated by tyrosine phosphorylation of LKB1.

Authors:  Eijiro Yamada; Jeffrey E Pessin; Irwin J Kurland; Gary J Schwartz; Claire C Bastie
Journal:  Cell Metab       Date:  2010-02-03       Impact factor: 27.287

Review 4.  Pathways of polyunsaturated fatty acid utilization: implications for brain function in neuropsychiatric health and disease.

Authors:  Joanne J Liu; Pnina Green; J John Mann; Stanley I Rapoport; M Elizabeth Sublette
Journal:  Brain Res       Date:  2014-12-08       Impact factor: 3.252

5.  A systems genetics approach implicates USF1, FADS3, and other causal candidate genes for familial combined hyperlipidemia.

Authors:  Christopher L Plaisier; Steve Horvath; Adriana Huertas-Vazquez; Ivette Cruz-Bautista; Miguel F Herrera; Teresa Tusie-Luna; Carlos Aguilar-Salinas; Päivi Pajukanta
Journal:  PLoS Genet       Date:  2009-09-11       Impact factor: 5.917

Review 6.  Fyn kinase function in lipid utilization: a new upstream regulator of AMPK activity?

Authors:  Manu Vatish; Eijiro Yamada; Jeffrey E Pessin; Claire C Bastie
Journal:  Arch Physiol Biochem       Date:  2009-10       Impact factor: 4.076

7.  Obesity induces preadipocyte CD36 expression promoting inflammation via the disruption of lysosomal calcium homeostasis and lysosome function.

Authors:  Xiaoxiao Luo; Yanping Li; Ping Yang; Yao Chen; Li Wei; Ting Yu; Jun Xia; Xiong Z Ruan; Lei Zhao; Yaxi Chen
Journal:  EBioMedicine       Date:  2020-06-06       Impact factor: 8.143

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.